DFG (HE 1376/38-1; SA 2902/2-1)

Link to this page

DFG (HE 1376/38-1; SA 2902/2-1)

Authors

Publications

Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.

Buzharevski, Antonio; Paskaš, Svetlana; Sárosi, Menyhárt-Botond; Laube, Markus; Lönnecke, Peter; Neumann, Wilma; Murganić, Blagoje; Mijatović, Sanja; Maksimović-Ivanić, Danijela; Pietzsch, Jens; Hey-Hawkins, Evamarie

(2020)

TY  - JOUR
AU  - Buzharevski, Antonio
AU  - Paskaš, Svetlana
AU  - Sárosi, Menyhárt-Botond
AU  - Laube, Markus
AU  - Lönnecke, Peter
AU  - Neumann, Wilma
AU  - Murganić, Blagoje
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Pietzsch, Jens
AU  - Hey-Hawkins, Evamarie
PY  - 2020
UR  - http://www.ncbi.nlm.nih.gov/pubmed/32179835
UR  - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7076013
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3640
AB  - Owing to the involvement of cyclooxygenase-2 (COX-2) in carcinogenesis, COX-2-selective inhibitors are increasingly studied for their potential cytotoxic properties. Moreover, the incorporation of carboranes in structures of established anti-inflammatory drugs can improve the potency and metabolic stability of the inhibitors. Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells. Furthermore, it was shown that the carborane-modified derivatives of rofecoxib showed different modes of action that were dependent on the cell type.
T2  - Scientific Reports
T1  - Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.
IS  - 1
VL  - 10
DO  - 10.1038/s41598-020-59059-3
SP  - 4827
ER  - 
@article{
author = "Buzharevski, Antonio and Paskaš, Svetlana and Sárosi, Menyhárt-Botond and Laube, Markus and Lönnecke, Peter and Neumann, Wilma and Murganić, Blagoje and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Pietzsch, Jens and Hey-Hawkins, Evamarie",
year = "2020",
abstract = "Owing to the involvement of cyclooxygenase-2 (COX-2) in carcinogenesis, COX-2-selective inhibitors are increasingly studied for their potential cytotoxic properties. Moreover, the incorporation of carboranes in structures of established anti-inflammatory drugs can improve the potency and metabolic stability of the inhibitors. Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells. Furthermore, it was shown that the carborane-modified derivatives of rofecoxib showed different modes of action that were dependent on the cell type.",
journal = "Scientific Reports",
title = "Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.",
number = "1",
volume = "10",
doi = "10.1038/s41598-020-59059-3",
pages = "4827"
}
Buzharevski, A., Paskaš, S., Sárosi, M., Laube, M., Lönnecke, P., Neumann, W., Murganić, B., Mijatović, S., Maksimović-Ivanić, D., Pietzsch, J.,& Hey-Hawkins, E.. (2020). Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.. in Scientific Reports, 10(1), 4827.
https://doi.org/10.1038/s41598-020-59059-3
Buzharevski A, Paskaš S, Sárosi M, Laube M, Lönnecke P, Neumann W, Murganić B, Mijatović S, Maksimović-Ivanić D, Pietzsch J, Hey-Hawkins E. Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.. in Scientific Reports. 2020;10(1):4827.
doi:10.1038/s41598-020-59059-3 .
Buzharevski, Antonio, Paskaš, Svetlana, Sárosi, Menyhárt-Botond, Laube, Markus, Lönnecke, Peter, Neumann, Wilma, Murganić, Blagoje, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Pietzsch, Jens, Hey-Hawkins, Evamarie, "Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells." in Scientific Reports, 10, no. 1 (2020):4827,
https://doi.org/10.1038/s41598-020-59059-3 . .
2
16
5
15